Premature newborns' need for transfusions declines with ESA use

06/18/2013 | Medscape (free registration)

Treating preterm infants with an erythropoiesis-stimulating agent such as darbepoetin alfa can help decrease the use of red blood cell transfusions, according to a study in the journal Pediatrics. Infants given the drugs in a trial at high-altitude hospitals were given fewer transfusions. Fifty-nine percent of infants administered darbepoetin alfa and 52% of infants given erythropoietin did not receive transfusions, compared with 38% for the placebo group.

View Full Article in:

Medscape (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager, Business Conduct
Gilead
Foster City, CA
Product Patent Attorney
Gilead
Foster City, CA
Employment Counsel
Gilead
Foster City, CA
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Global Counsel - Advertising and Promotions
Mylan Inc.
Washington, DC